ヨサフォン・ヴィチエンヴァニッチクル医師は、バンコクのイントララット病院の内科専門医です。様々な急性および長期的な疾患を持つ患者を治療しています。ヴィチエンヴァニッチクル医師は、スリナカリンウィロート大学で医学の学位を取得しました。また、タイ王国空軍医学部から内科の認定証も取得しています。
フォックス・ヴィオラ博士は、BKZゾーリンゲン血液腫瘍科・緩和医療科の主任医師です。同クリニックは、認定された集学的腫瘍センターです。フォックス博士は、ドイツおよびヨーロッパにおける腫瘍性疾患の薬物療法の第一人者であり、15年以上の臨床経験を有しています。
同博士は、ドイツ腫瘍学・血液腫瘍学会（GDHO）、ドイツ医師会、およびアメリカがん研究学会に所属しています。また、分子生物学の研究にも従事しており、その研究成果はがん治療および分子診断の発展に貢献しています。
主な専門領域は、化学療法、免疫療法、分子標的療法、および放射線療法です。フォックス博士は、革新的な治療法と患者への細やかな配慮で知られています。その取り組みにより、高い治癒率を達成し、同僚からの高い評価を得ています。
Liu Shi Xin博士は、中国医師会放射線腫瘍学分会の副会長です。彼は厦門ヒューマニティ病院腫瘍センターの学科長を務めています。Liu博士は、胸部および腹部がんの精密放射線治療を専門としています。彼は、医療への貢献に対して国務院特別政府手当を受けています。
ヴィクトル・アレクサンダー・クロール医師は、デュッセルドルフの聖マルティヌス病院の消化器内科および内科の部長です。また、認定された肥満治療センターの責任者も務めています。クロール医師は、消化管、代謝、呼吸器系の複雑な疾患を治療しています。国際肥満外科連盟の認定を受けたドイツ国内でわずか2つのクリニックのうちの1つで勤務しています。
セバスチャン・カイル教授は、ゾーリンゲン大学病院の放射線科主任医師です。高精度画像診断および全身の断面診断を専門としています。
バハ・ゼンゲル医師は、メディカルポイント国際病院の一般外科医です。腫瘍形成乳房外科および甲状腺疾患を専門としています。ドクズ・エイリュル大学で基礎腫瘍学の博士号を取得。ゼンゲル医師は、基礎腫瘍学協会の創設理事を務めています。イズミルにあるJCI認定施設で勤務しています。
セヴリーヌ・イボラ医師は、ゾーリンゲン医療センターの産婦人科部長です。婦人科腫瘍学およびハイリスク周産期医療を専門としています。イボラ医師は、低侵襲がん手術にダヴィンチ・ロボットシステムを使用しています。子宮頸部病理学およびウロギネコロジー（女性泌尿器科）の認定専門医です。
サメット・エリンチ医師は、イスタンブールのVMメディカルパーク・フロリヤ病院の整形外科脊椎外科医です。ロボット支援による膝関節置換術および複雑な骨変形矯正の専門家です。エリンチ医師は米国シカゴのロヨラ大学で研修を受けました。小児脊柱側弯症および変性脊椎疾患の治療を専門としています。
ムスタファ・セルカン・アレムダル医師は、メディカルパーク・アンタルヤ病院コンプレックスの臨床腫瘍医です。複雑な固形腫瘍および血液がんの治療を専門としています。アレムダル医師は、アクデニズ大学で医学の学位を取得し、腫瘍学のフェローシップを修了しました。トルコ臨床腫瘍学会の活動的なメンバーです。
イ・ソクグ教授は、ミョンジ病院の肝移植外科における第一人者です。これまでに約2,000例の肝移植手術を手がけました。韓国初の無輸血肝移植を成功させたほか、生後1ヶ月の乳児に対する肝細胞移植を実施しました。また、急性肝不全に対するバイオ人工肝臓の臨床使用を初めて主導しました。さらに、エジプトでの生体肝移植手術の執刀や、ベトナムの医療チームへの指導も行っています。
現在はミョンジ病院の外科学教授を務めており、サムスンソウル病院の臓器移植センター長を歴任しました。ソウル大学校で医学士および修士号を、カトリック大学校で医学博士号を取得しています。ボストン小児病院／ハーバード大学でフェローシップを修了し、ジョンズ・ホプキンス大学で移植研修を受けました。移植外科学および小児外科学の分野で3つの国内学会の会長を歴任しました。チョン・クンダン学術賞、ファイザー臨床医学賞、アステラス研究者賞など、数多くの受賞歴があります。447本の学術論文と13冊の著書（章担当）を発表しています。
ハサン・ムトル医師は、メディカルパーク・アンタルヤ病院コンプレックスの腫瘍内科医です。免疫療法、がんの標的療法、がん治療における遺伝子研究を専門としています。ムトル医師はハジェテペ大学で医学の学位を取得しました。医学教授の称号を保持しています。ムトル医師は、臓器腫瘍の診断と化学療法に注力しています。
医師は2022年にマヒドン大学ラマティボディ病院医学部で医学博士号を取得しました。専門的な診療は、一般的な疾患の診断、治療、および包括的なウェルネスケアに重点を置いています。
医師は、米国アンチエイジング・再生医療委員会（ABAARM）によるアンチエイジング・再生医療の認定、および米国ナチュロパシー認定委員会（ANCB）による栄養ウェルネスの認定を含む専門資格を保持しています。医師はタイ語と英語の両方に堪能です。
ボアズ・リーバーマン医師は、シェバ医療センターの整形外科腫瘍科の部長です。成人および小児の骨軟部肉腫の治療を専門としています。リーバーマン医師は、フォーブス誌のイスラエルのトップドクターリストに選出されました。機能的再建を伴う四肢温存がん手術に注力しています。リーバーマン医師は、トロントのマウントサイナイ病院およびプリンセス・マーガレットがんセンターでフェローシップを修了しました。
Yan Zhi Ping医師は、Xiamen Humanity Hospitalの放射線科を統括しています。全身CTスキャンを用いたがんの早期発見を専門としています。
イルファン・ジチン医師は、イスティニエ大学リヴ病院トプカプの腫瘍内科教授です。膠芽腫、肺がん、膵臓腫瘍などの複雑な癌の治療を専門としています。トラキア大学医学部の教授も務めています。ジチン医師は以前、トルコ空軍の医師として勤務していました。
ムハンメド・ムスタファ・アトチ医師は、Liv Hospital Topkapıの腫瘍内科准教授です。大腸がん、乳がん、胃がん、肺がんの治療を専門としています。以前は、ジェミル・タシュジオール教授記念市立病院で教育コーディネーターを務めていました。アトチ医師は、米国臨床腫瘍学会（ASCO）の会員です。
ベニ・ブルシ教授は、シェバ医療センターの腫瘍内科および内科の二重認定専門医です。全身CTスキャンを用いて、がんの早期発見を行っています。
ヤーコフ・ローレンス医師は、シェバ医療センターの放射線腫瘍科部長です。精密放射線治療と神経腫瘍学を専門としています。ローレンス医師は、膵臓がんの疼痛管理のための腹腔神経叢ラジオサージェリー（放射線外科）の先駆者です。専門分野における最高の名誉の一つであるFASTROの称号を保持しています。
ヤイール・バー博士は、シェバ医療センターの癌センターの副所長であり、胸部腫瘍内科医です。進行非小細胞肺癌の治療において、個別化免疫療法および標的療法を専門としています。分子生物学の博士号（PhD）を取得しており、免疫療法耐性に焦点を当てた研究室を主導しています。
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.